Viralym-M

HSCT recipients are highly susceptible to severe viral reactivation caused by:

  • Adenovirus (AdV)
  • BK virus (BKV)
  • Cytomegalovirus (CMV)
  • Epstein-Barr virus (EBV)
  • Human herpesvirus-6 (HHV-6)

Viralym-M

Viralym-M is a “ready to administer” single T cell product that treats up to 5 different viral infections simultaneously (AdV, BKV, CMV, EBV, HHV-6). Viralym-M is being evaluated in a Phase 2 clinical study which is currently open for patient recruitment at Texas Children’s Hospital and the Methodist Hospital in Houston, TX. For more information, please visit ClincialTrials.gov: NCT02108522

ClincialTrials.gov: NCT02108522